HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NFU1
NFU1 iron-sulfur cluster scaffold
Chromosome 2 Β· 2p13.3
NCBI Gene: 27247Ensembl: ENSG00000169599.14HGNC: HGNC:16287UniProt: Q9UMS0
54PubMed Papers
22Diseases
0Drugs
18Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
iron ion bindingprotein bindingmitochondrionnucleusmultiple mitochondrial dysfunctions syndrome 1Fatal multiple mitochondrial dysfunction syndrome type 1Fatal multiple mitochondrial dysfunction syndromeneurodegenerative disease
✦AI Summary

NFU1 is a mitochondrial iron-sulfur cluster scaffold protein that assembles [4Fe-4S] clusters and delivers them to target proteins 1. Mechanistically, NFU1 functions as a key component in late-stage [4Fe-4S] cluster maturation, where ISCA1 orchestrates the coordinated interaction between ISCA2 and NFU1 to facilitate cluster transfer from the ISCA1-ISCA2 assembly complex to recipient apo proteins 2. The structural plasticity of NFU1's N- and C-terminal domains is crucial for protein partner recognition and modulating cluster trafficking 3. NFU1 mutations cause Multiple Mitochondrial Dysfunction Syndrome 1 (MMDS1) and spastic paraplegia 93, characterized by severe mitochondrial respiratory chain defects, impaired complex II and pyruvate dehydrogenase activity, and reduced lipoic acid biosynthesis 145. Clinically, NFU1 deficiency leads to mitochondrial encephalomyopathies, early-life death, and pulmonary arterial hypertension with ~70% penetrance in patients with the G208C mutation 67. Disease mechanisms include elevated mtDNA mutability and oxidative stress 4. Lipoic acid supplementation alleviates mitochondrial dysfunction and angiogenic deficiency in NFU1-deficient models, suggesting therapeutic potential 7.

Sources cited
1
NFU1 mutations cause mitochondrial disorders through defects in iron-sulfur cluster assembly, leading to respiratory chain dysfunction and mitochondrial encephalomyopathies
PMID: 27381105
2
ISCA1 orchestrates NFU1 and ISCA2 interaction to coordinate [4Fe-4S] cluster transfer to mitochondrial apo proteins
PMID: 33711344
3
NFU1 structural plasticity in N- and C-terminal domains is crucial for protein-protein recognition and [4Fe-4S] cluster transfer
PMID: 37211204
4
NFU1 mutations cause Multiple Mitochondrial Dysfunction Syndrome 1 with effects on mitochondrial respiration, oxidative stress, and mtDNA stability
PMID: 40233434
5
NFU1 defects impair LIAS function and lipoic acid synthesis, affecting multiple 2-oxoacid dehydrogenases in energy metabolism
PMID: 24777537
6
NFU1 G208C mutation causes pulmonary hypertension with ~70% penetrance and greater prevalence in females; decreases Complex II and pyruvate dehydrogenase activity
PMID: 31461310
7
NFU1 mitochondrial dysfunction impairs pulmonary angiogenesis; lipoic acid supplementation restores mitochondrial function and rescues PAH phenotype
PMID: 39320470
8
RNA-seq identified a splice isoform switch due to non-coding variant in NFU1, revealing novel disease mechanisms
PMID: 40597352
Disease Associationsβ“˜22
multiple mitochondrial dysfunctions syndrome 1Open Targets
0.82Strong
Fatal multiple mitochondrial dysfunction syndrome type 1Open Targets
0.66Moderate
Fatal multiple mitochondrial dysfunction syndromeOpen Targets
0.57Moderate
neurodegenerative diseaseOpen Targets
0.56Moderate
spastic paraplegia 93, autosomal recessiveOpen Targets
0.53Moderate
Fatal multiple mitochondrial dysfunction syndrome type 2Open Targets
0.41Moderate
denturesOpen Targets
0.39Weak
mitochondrial diseaseOpen Targets
0.37Weak
osteoarthritis, hipOpen Targets
0.34Weak
hypertensionOpen Targets
0.33Weak
spinal stenosisOpen Targets
0.26Weak
vertebral column disorderOpen Targets
0.24Weak
essential hypertensionOpen Targets
0.23Weak
Low back painOpen Targets
0.22Weak
dental cariesOpen Targets
0.20Weak
radiculitisOpen Targets
0.19Weak
SciaticaOpen Targets
0.19Weak
genetic disorderOpen Targets
0.19Weak
cervical disc degenerative disorderOpen Targets
0.17Weak
coronary artery diseaseOpen Targets
0.16Weak
Multiple mitochondrial dysfunctions syndrome 1UniProt
Spastic paraplegia 93, autosomal recessiveUniProt
Pathogenic Variants18
NM_001002755.4(NFU1):c.303-2A>TLikely pathogenic
not provided|Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜…β˜†β˜†2026
NM_001002755.4(NFU1):c.545G>A (p.Arg182Gln)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1|NFU1-related disorder|Uterine corpus endometrial carcinoma|Spastic paraplegia 93, autosomal recessive
β˜…β˜…β˜†β˜†2025β†’ Residue 182
NM_001002755.4(NFU1):c.62+89G>APathogenic
NFU1-related disorder|Multiple mitochondrial dysfunctions syndrome 1|Spastic paraplegia 93, autosomal recessive
β˜…β˜…β˜†β˜†2025
NM_001002755.4(NFU1):c.544C>T (p.Arg182Trp)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 182
NM_001002755.4(NFU1):c.622G>T (p.Gly208Cys)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1|not provided|NFU1-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 208
NM_001002755.4(NFU1):c.545+5G>APathogenic
Multiple mitochondrial dysfunctions syndrome 1|not provided|Familial cancer of breast
β˜…β˜…β˜†β˜†2022
NM_001002755.4(NFU1):c.239_240del (p.Val80fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 80
NM_001002755.4(NFU1):c.507del (p.Val170fs)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜†β˜†β˜†2024β†’ Residue 170
NM_001002755.4(NFU1):c.264del (p.Thr90fs)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜†β˜†β˜†2024β†’ Residue 90
NM_001002755.4(NFU1):c.545G>T (p.Arg182Leu)Likely pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜†β˜†β˜†2020β†’ Residue 182
NM_001002755.4(NFU1):c.565G>A (p.Gly189Arg)Likely pathogenic
Multiple mitochondrial dysfunctions syndrome 1|Spastic paraplegia 93, autosomal recessive
β˜…β˜†β˜†β˜†2020β†’ Residue 189
NM_001002755.4(NFU1):c.485-1G>CLikely pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜†β˜†β˜†2019
NC_000002.11:g.(?_69627476)_(69627690_?)dupLikely pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜…β˜†β˜†β˜†2018
NM_001002755.4(NFU1):c.295C>G (p.Leu99Val)Pathogenic
Spastic paraplegia 93, autosomal recessive
β˜†β˜†β˜†β˜†2024β†’ Residue 99
NM_001002755.4(NFU1):c.263T>C (p.Phe88Ser)Pathogenic
Spastic paraplegia 93, autosomal recessive
β˜†β˜†β˜†β˜†2024β†’ Residue 88
NM_001002755.4(NFU1):c.62G>C (p.Arg21Pro)Pathogenic
Multiple mitochondrial dysfunctions syndrome 1
β˜†β˜†β˜†β˜†2024β†’ Residue 21
NM_001002755.4(NFU1):c.362T>C (p.Val121Ala)Pathogenic
Spastic paraplegia 93, autosomal recessive
β˜†β˜†β˜†β˜†2024β†’ Residue 121
NM_001002755.4(NFU1):c.721G>C (p.Val241Leu)Pathogenic
Spastic paraplegia 93, autosomal recessive
β˜†β˜†β˜†β˜†2024β†’ Residue 241
View on ClinVar β†—
Related Genes
CIAO1Shared pathway100%CIAO2AShared pathway100%MMS19Shared pathway100%LIPT1Protein interaction100%SDHDProtein interaction89%ABCB7Protein interaction87%
Tissue Expression6 tissues
Heart
100%
Brain
62%
Ovary
38%
Lung
37%
Liver
35%
Bone Marrow
33%
Gene Interaction Network
Click a node to explore
NFU1CIAO1CIAO2AMMS19LIPT1SDHDABCB7
PROTEIN STRUCTURE
Preparing viewer…
PDB2LTM Β· NMR
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.54LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.96 [0.61–1.54]
RankingsWhere NFU1 stands among ~20K protein-coding genes
  • #8,346of 20,598
    Most Researched54
  • #2,293of 5,498
    Most Pathogenic Variants18
  • #15,409of 17,882
    Most Constrained (LOEUF)1.54
Genes detectedNFU1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
NFU1 gene mutation and mitochondrial disorders.
PMID: 27381105
Neurol India Β· 2016
1.00
2
ISCA1 Orchestrates ISCA2 and NFU1 in the Maturation of Human Mitochondrial [4Fe-4S] Proteins.
PMID: 33711344
J Mol Biol Β· 2021
0.90
3
Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension.
PMID: 39320470
J Exp Med Β· 2024
0.80
4
Yeast models of mutations in NFU1 gene for biochemical characterization and drug screening.
PMID: 40233434
Biochem Biophys Res Commun Β· 2025
0.70
5
Clinical applications of and molecular insights from RNA sequencing in a rare disease cohort.
PMID: 40597352
Genome Med Β· 2025
0.60